Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
AlphaMedix™ (²¹²Pb-DOTAMTATE) is a radiotherapeutic drug indicated in subjects with
unresectable, metastatic somatostatin receptor (SSTR) positive neuroendocrine tumors (NETs).
Because 212Pb is an in vivo generator of alpha particles, it is particularly suitable for
SSTR therapy applications.
This drug addresses an unmet need in the field of peptide receptor radionuclide therapy
(PRRT) for NETs. Substitution of an alpha emitter (²¹²Pb) for the beta emitters currently
being used (i.e., 177Lu or 90Y) will provide significantly higher Linear Energy Transfer
(LET) and a shorter path length. Higher LET particles should cause more tumor cell death.
Shorter path length should result in less collateral damage of the normal tissue and
therefore less side effects for subjects receiving the drug.